Industries > Pharma > Global Hereditary Angioedema Market Forecast 2018-2028
Global Hereditary Angioedema Market Forecast 2018-2028
C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze, Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies
The global hereditary angioedema market is expected to grow at a CAGR of 8.8% in the first half of the forecast period. In 2017, the C1 Esterase Inhibitor segment held 42% of this market.
How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.
In this brand new 232-page report you will receive 82 tables and 130 figures– all unavailable elsewhere.
The 232-page report provides clear detailed insight into the global hereditary angioedema market. Discover the key drivers and challenges affecting the market.
By ordering and reading our brand-new report today you stay better informed and ready to act.
Report Scope
• Global Hereditary Angioedema Market Forecast from 2018-2028
• This report also breaks down the revenue forecast for the global hereditary angioedema market by drug class:
• C1 Esterase Inhibitor: Cinryze, Berinert, Ruconest
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor (Kalbitor)
This report also provides a market attractiveness index by drug class.
• This report also breaks down the revenue forecast for the global hereditary angioedema market by route of administration:
• Intravenous
• Subcutaneous Injection
• Oral
This report also provides a market attractiveness index by route of administration.
• This report also breaks down the revenue forecast for the global hereditary angioedema market by distribution channel:
• Hospital Pharmacies
• Retail Pharmacies
This report also provides a market attractiveness index by distribution channel
• This report provides individual revenue forecasts to 2028 for these regional and national markets:
• North America: The U.S., Canada
• Latin America: Brazil, Mexico, Rest of Latin America
• Europe: U.K., Germany, Spain, France, Italy, Russia, Rest of Europe
• Asia-Pacific: China, India, Japan, Australia and New Zealand, South Korea, ASEAN, Rest of Asia-Pacific
• Middle East: GCC Countries, Israel, Rest of Middle East
• Africa: South Africa, Central Africa, North Africa
This report also provides a market attractiveness index by region
The forecast for each regional market is further broken down by drug class, product, route of administration and distribution channel
This report provides a market attractiveness index by drug class, product, route of administration and distribution channel for each regional market
• Our study discusses the selected leading companies that are the major players in the global hereditary angioedema industry:
• BioCryst Pharmaceuticals, Inc.
• CSL Limited
• iBio, Inc.
• Ionis Pharmaceuticals, Inc.
• Pharming Group NV
• Santarus, Inc.
• Shire PLC
• This report discusses factors that drive and restrain the market, as well as trends and opportunities.
Visiongain’s study is intended for anyone requiring commercial analyses for the global hereditary angioedema market. You find data, trends and predictions.
Buy our report today Global Hereditary Angioedema Market Forecast 2018-2028: C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor (Kalbitor), Cinryze. Berinert, Ruconest, Intravenous, Subcutaneous Injection, Oral, Hospital Pharmacies, Retail Pharmacies.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
1. Report Overview
1.1. Global Hereditary Angioedema Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report Include:
1.5. Who is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.6.3. Market Evaluation & Forecasting Methodology
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain
2. Introduction to the Hereditary Angioedema Market
2.1. Hereditary Angioedema Market Structure
2.2. Hereditary Angioedema Market Definition
2.3. Hereditary Angioedema C1 Esterase Inhibitor Drug Class Submarket Definition
2.4. Hereditary Angioedema Intravenous Injection Route of Administration Submarket Definition
2.5. Hereditary Angioedema Market Taxonomy
2.6. Global Hereditary Angioedema Market Snapshot
2.7. Global Hereditary Angioedema Market Dynamics
2.7.1. Global Hereditary Angioedema Market: Drivers
2.7.1.1 Increasing diagnosis in the U.S. and Europe
2.7.1.2 Increasing per capita income
2.7.1.3 Changing lifestyle
2.7.1.4 Adoption of emerging therapies
2.7.1.5 Rising Healthcare Cost
2.7.1.6 Patient Awareness for Better Products
2.7.2. Global Hereditary Angioedema Market: Restraints
2.7.2.1 Lack of awareness about Hereditary Angioedema Disorder
2.7.2.2 Few approved specialty HAE drugs that are expensive
2.7.3. Global Hereditary Angioedema Market: Trends
2.7.3.1 Orphan drugs for the treatment of HAE
2.7.3.2 Expensive nature of treatments
2.8. Global Hereditary Angioedema Market: Opportunities
2.8.1 Upcoming Novel Drugs
3. Global Hereditary Angioedema Market by Drug Class, 2018-2028
3.1. Global Hereditary Angioedema Market Size and Forecast by Drug Class
3.1.1. C1 Esterase Inhibitor Submarket Forecast 2018-2028
3.1.2. Selective Bradykinin B2 Receptor Antagonist Submarket Forecast 2018-2028
3.1.3. Kallikrein Inhibitor (Kalbitor) Submarket Forecast 2018-2028
3.1.4. Others Submarket Forecast 2018-2028
3.2. Global Hereditary Angioedema Market Attractiveness Index by Drug Class
4. Global Hereditary Angioedema Market by Route of Administration, 2018-2028
4.1. Global Hereditary Angioedema Market Size and Forecast by Route of Administration
4.1.1. Intravenous Segment Submarket 2018-2028
4.1.2. Subcutaneous Injection Submarket 2018-2028
4.1.3. Oral Segment Submarket 2018-2028
4.2. Global Hereditary Angioedema Market Attractiveness Index by Route of Administration
5. Global Hereditary Angioedema Market by Distribution Channel, 2018-2028
5.1. Global Hereditary Angioedema Market Size and Forecast by Distribution Channel
5.1.1. Hospital Pharmacies Submarket 2018-2028
5.1.2. Retail Pharmacies Submarket 2018-2028
5.2. Global Hereditary Angioedema Market Attractiveness Index by Distribution Channel
6. Global Hereditary Angioedema Market by Region, 2018-2028
6.1. Global Hereditary Angioedema Market Size and Forecast by Region
6.1.1. North America Hereditary Angioedema Market Forecast 2018-2028
6.1.2. Latin America Hereditary Angioedema Market Forecast 2018-2028
6.1.3. Europe Hereditary Angioedema Market Forecast 2018-2028
6.1.4. Asia - Pacific Hereditary Angioedema Market Forecast 2018-2028
6.1.5. Middle East Hereditary Angioedema Market Forecast 2018-2028
6.1.6. Africa Hereditary Angioedema Market Forecast 2018-2028
6.2. Global Hereditary Angioedema Market Attractiveness Index by Region
6.3. Leading Hereditary Angioedema Market Forecast by Region: 2018-2028
7. North America Hereditary Angioedema Market Analysis and Forecast, 2018-2028
7.1. North America Hereditary Angioedema Market Forecast by Country, 2018-2028
7.1.1. U.S. Hereditary Angioedema Market Forecast 2018-2028
7.1.2. Canada Hereditary Angioedema Market Forecast 2018-2028
7.2. North America Hereditary Angioedema Market by Drug Class
7.2.1. North America Hereditary Angioedema Market by Product, 2017-2028
7.3. North America Hereditary Angioedema Market by Route of Administration, 2017-2028
7.4. North America Hereditary Angioedema Market by Distribution Channel, 2017-2028
7.5. North America Hereditary Angioedema Market Attractiveness Index
7.5.1. By Drug Class
7.5.2. By Route of Administration
7.5.3. By Distribution Channel
7.5.4. By Country
8. Latin America Hereditary Angioedema Market Analysis and Forecast, 2018-2028
8.1. Latin America Hereditary Angioedema Market Forecast by Country, 2018-2028
8.1.1. Brazil Hereditary Angioedema Market Forecast 2018-2028
8.1.2. Mexico Hereditary Angioedema Market Forecast 2018-2028
8.1.3. Rest of Latin America Hereditary Angioedema Market Forecast 2018-2028
8.2. Latin America Hereditary Angioedema Market by Drug Class
8.2.1. Latin America Hereditary Angioedema Market by Product
8.3. Latin America Hereditary Angioedema Market by Route of Administration
8.4. Latin America Hereditary Angioedema Market by Distribution Channel
8.5. Latin America Hereditary Angioedema Market Attractiveness Index
8.5.1. By Drug Class
8.5.2. By Route of Administration
8.5.3. By Distribution Channel
8.5.4. By Country
9. Europe Hereditary Angioedema Market Analysis and Forecast, 2018-2028
9.1. Europe Hereditary Angioedema Market Forecast by Country, 2018-2028
9.1.1. U.K. Hereditary Angioedema Market Forecast 2018-2028
9.1.2. France Hereditary Angioedema Market Forecast 2018-2028
9.1.3. Germany Hereditary Angioedema Market Forecast 2018-2028
9.1.4. Italy Hereditary Angioedema Market Forecast 2018-2028
9.1.5. Spain Hereditary Angioedema Market Forecast 2018-2028
9.1.6. Russia Hereditary Angioedema Market Forecast 2018-2028
9.1.7. Rest of Europe Hereditary Angioedema Market Forecast 2018-2028
9.2. Europe Hereditary Angioedema Market by Drug Class
9.2.1. Europe Hereditary Angioedema Market by Product
9.3. Europe Hereditary Angioedema Market by Route of Administration
9.4. Europe Hereditary Angioedema Market by Distribution Channel
9.5. Europe Hereditary Angioedema Market Attractiveness Index
9.5.1. By Drug Class
9.5.2. By Route of Administration
9.5.3. By Distribution Channel
9.5.4. By Country
10. Asia-Pacific Hereditary Angioedema Market Analysis and Forecast, 2018-2028
10.1. Asia-Pacific Hereditary Angioedema Market Forecast by Country, 2018-2028
10.1.1. China Hereditary Angioedema Market Forecast 2018-2028
10.1.2. India Hereditary Angioedema Market Forecast 2018-2028
10.1.3. Australia and New Zealand Hereditary Angioedema Market Forecast 2018-2028
10.1.4. Japan Hereditary Angioedema Market Forecast 2018-2028
10.1.5. ASEAN Hereditary Angioedema Market Forecast 2018-2028
10.1.6. South Korea Hereditary Angioedema Market Forecast 2018-2028
10.1.7. Rest of Asia-Pacific Hereditary Angioedema Market Forecast 2018-2028
10.2. Asia-Pacific Hereditary Angioedema Market by Drug Class
10.2.1. Asia-Pacific Hereditary Angioedema Market by Product
10.3. Asia-Pacific Hereditary Angioedema Market by Route of Administration
10.4. Asia-Pacific Hereditary Angioedema Market by Distribution Channel
10.5. Asia-Pacific Hereditary Angioedema Market Attractiveness Index
10.5.1. By Drug Class
10.5.2. By Route of Administration
10.5.3. By Distribution Channel
10.5.4. By Country
11. Middle East Hereditary Angioedema Market Analysis and Forecast, 2018-2028
11.1. Middle East Hereditary Angioedema Market Forecast by Country, 2018-2028
11.1.1. GCC Countries Angioedema Market Forecast 2018-2028
11.1.2. Israel Angioedema Market Forecast 2018-2028
11.1.3. Rest of Middle East Angioedema Market Forecast 2018-2028
11.2. Middle East Hereditary Angioedema Market by Drug Class
11.2.1. Middle East Hereditary Angioedema Market by Product
11.3. Middle East Hereditary Angioedema Market by Route of Administration
11.4. Middle East Hereditary Angioedema Market by Distribution Channel
11.5. Middle East Hereditary Angioedema Market Attractiveness Index
11.5.1. By Drug Class
11.5.2. By Route of Administration
11.5.3. By Distribution Channel
11.5.4. By Country
12. Africa Hereditary Angioedema Market Analysis and Forecast, 2018-2028
12.1. Africa Hereditary Angioedema Market Forecast by Country, 2018-2028
12.1.1. South Africa Hereditary Angioedema Market Forecast 2018-2028
12.1.2. Central Africa Hereditary Angioedema Market Forecast 2018-2028
12.1.3. North Africa Hereditary Angioedema Market Forecast 2018-2028
12.2. Africa Hereditary Angioedema Market by Drug Class
12.2.1. Africa Hereditary Angioedema Market by Product
12.3. Africa Hereditary Angioedema Market by Route of Administration
12.4. Africa Hereditary Angioedema Market by Distribution Channel
12.5. Africa Hereditary Angioedema Market Attractiveness Index
12.5.1. By Drug Class
12.5.2. By Route of Administration
12.5.3. By Distribution Channel
12.5.4. By Country
13. Company Profiles
13.1. BioCryst Pharmaceutical, Inc.
13.2. CSL LIMITED
13.3. IBIO INC.
13.4. IONIS PHARMACEUTICALS, INC.
13.5. PHARMING GROUP NV
13.6. SANTARUS, INC.
13.7. SHIRE PLC
14. Conclusion
Appendices
Associated Visiongain Reports
Visiongain Report Sales Order Form
Appendix A
About visiongain
Appendix B
Visiongain report evaluation form
List of Tables
Table 2.1 Global Hereditary Angioedema Market - Segmentation
Table 2.2 Global Hereditary Angioedema Market Forecast; ($bn, AGR %, CAGR %), 2017-2028
Table 3.1 Global Hereditary Angioedema Market Forecast by Drug Class: ($bn, AGR %, CAGR %), 2017-2028
Table 3.2 Global Hereditary Angioedema Market by Drug Class Forecast: (CAGR %), 2018-2023, 2023-2028, 2018-2028
Table 4.1 Global Hereditary Angioedema Market Forecast by Route of Administration: ($bn, AGR%, CAGR%), 2017-2028
Table 4.2 Global Hereditary Angioedema Market by Route of Administration Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 5.1 Global Hereditary Angioedema Market Forecast by Distribution Channel: ($bn, AGR%, CAGR%), 2017-2028
Table 5.2 Global Hereditary Angioedema Market by Distribution Channel Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 6.1 Global Hereditary Angioedema Market Forecast by Region: ($bn, AGR%, CAGR %), 2017-2028
Table 6.2 Global Hereditary Angioedema Market by Region: CAGR (%) 2018-2023, 2023-2028, 2018-2028
Table 6.3 Leading Hereditary Angioedema Market by Region Forecast: ($bn, AGR %), 2018-2028
Table 7.1 North Hereditary Angioedema Market Forecast: ($bn, AGR %, CAGR %), 2017-2028
Table 7.2 North America Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2018-2028
Table 7.3 North America Hereditary Angioedema Market Forecast by Drug Class: ($bn, AGR %, CAGR%), 2017-2028
Table 7.4 North America Hereditary Angioedema Market by Drug Class: CAGR (%) 2018-2023, 2023-2028, 2018-2028
Table 7.5 North America Hereditary Angioedema Market by Product Forecast: ($bn, AGR %), 2017-2028
Table 7.6 North America Hereditary Angioedema Market by Route of Administration Forecast: ($bn, AGR %, CAGR %), 2017-2028
Table 7.7 North America Hereditary Angioedema Market by Route of Administration Forecast: CAGR (%) 2018-2023, 2023-2028, 2018-2028
Table 7.8 North America Hereditary Angioedema Market by Distribution Channel Forecast: ($bn, AGR %), 2017-2028
Table 7.9 North America Hereditary Angioedema Market Forecast by Distribution Channel: ($bn, AGR %, CAGR%), 2017-2028
Table 7.10 North America Hereditary Angioedema Market by Distribution Channel Forecast: CAGR (%) 2018-2023, 2023-2028, 2018-2028
Table 8.1 Latin America Hereditary Angioedema Market Forecast: ($bn, AGR %, CAGR %), 2017-2028
Table 8.2 Latin America Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Table 8.3 Latin America Hereditary Angioedema Market by Drug Class Forecast: ($bn, AGR %), 2017-2028
Table 8.4 Latin America Hereditary Angioedema Market Forecast by Drug Class: ($bn, AGR%), 2017-2028
Table 8.5 Latin America Hereditary Angioedema Market by Drug Class Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 8.6 Latin America Hereditary Angioedema Market by Product Forecast: ($bn, AGR %), 2017-2028
Table 8.7 Latin America Hereditary Angioedema Market by Route of Administration Forecast: ($bn, AGR %), 2017-2028
Table 8.8 Latin America Hereditary Angioedema Market Forecast by Route of Administration: ($bn, AGR%, CAGR%), 2017-2028
Table 8.9 Latin America Hereditary Angioedema Market by Route of Administration Forecast: (CAGR%), 2018-2023, 2023-2028, 2018-2028
Table 8.10 Latin America Hereditary Angioedema Market Forecast by Distribution Channel: ($bn, AGR%, CAGR%) 2017-2028
Table 8.11 Latin America Hereditary Angioedema Market by Distribution Channel CAGR (%) Forecast 2018-2023, 2023-2028, 2018-2028
Table 9.1 Europe Hereditary Angioedema Market Forecast: ($bn, AGR%, CAGR%) 2017-2028
Table 9.2 Europe Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Table 9.3 Europe Hereditary Angioedema Market Forecast by Drug Class: ($bn, AGR%, CAGR%) 2017-2028
Table 9.4 Europe Hereditary Angioedema Market by Drug Class Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 9.5 Europe Hereditary Angioedema Market by Product Forecast: ($bn, AGR %), 2017-2028
Table 9.6 Europe Hereditary Angioedema Market by Route of Administration Forecast: ($bn, AGR %), 2017-2028
Table 9.7 Europe Hereditary Angioedema Market Forecast by Route of Administration: ($bn, AGR%, CAGR%), 2017-2028
Table 9.8 Europe Hereditary Angioedema Market by Route of Administration Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 9.9 Europe Hereditary Angioedema Market Forecast by Distribution Channel: ($bn, AGR %, CAGR %) 2018-2028
Table 9.10 Europe Hereditary Angioedema Market by Distribution Channel Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 10.1 Asia-Pacific Hereditary Angioedema Market Forecast: ($bn, AGR %, CAGR%), 2017-2028
Table 10.2 Asia-Pacific Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Table 10.3 Asia-Pacific Hereditary Angioedema Market Forecast by Drug Class ($bn, AGR %, CAGR%) 2017-2028
Table 10.4 Asia-Pacific Hereditary Angioedema Market by Drug Class Segment Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 10.5 Asia-Pacific Hereditary Angioedema Market by Product Forecast: ($bn, AGR %), 2017-2028
Table 10.6 Asia-Pacific Hereditary Angioedema Market by Route of Administration Forecast: ($bn, AGR %), 2017-2028
Table 10.7 Asia-Pacific Hereditary Angioedema Market Forecast by Route of Administration: ($bn, AGR%, CAGR%), 2017-2028
Table 10.8 Asia-Pacific Hereditary Angioedema Market by Route of Administration Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 10.9 Asia-Pacific Hereditary Angioedema Market Forecast by Distribution Channel: ($bn, AGR %, CAGR %), 2017-2028
Table 10.10 Asia-Pacific Hereditary Angioedema Market by Distribution Channel Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 11.1 Middle East Hereditary Angioedema Market Forecast: ($bn, AGR %, CAGR%), 2017-2028
Table 11.2 Middle East Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Table 11.3 Middle East Hereditary Angioedema Market Forecast by Drug Class: ($bn, AGR%, CAGR%) 2017-2028
Table 11.4 Middle East Hereditary Angioedema Market by Drug Class Segment Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 11.5 Middle East Hereditary Angioedema Market by Product Forecast: ($bn, AGR %), 2017-2028
Table 11.6 Middle East Hereditary Angioedema Market Forecast by Route of Administration: ($bn, AGR %), 2017-2028
Table 11.7 Middle East Hereditary Angioedema Market by Route of Administration Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 11.8 Middle East Hereditary Angioedema Market by Distribution Channel Forecast: ($bn, AGR %), 2017-2028
Table 11.9 Middle East Hereditary Angioedema Market Forecast by Distribution Channel ($bn, AGR %, CAGR %) 2017-2028
Table 11.10 Middle East Hereditary Angioedema Market by Distribution Channel Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 12.1 Africa Hereditary Angioedema Market Forecast: ($bn, AGR%, CAGR%), 2017-2028
Table 12.2 Africa Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Table 12.3 Africa Hereditary Angioedema Market Forecast by Drug Class ($bn, AGR%, CAGR%) 2017-2028
Table 12.4 Africa Hereditary Angioedema Market by Drug Class Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 12.5 Africa Hereditary Angioedema Market by Product Forecast: ($bn, AGR %), 2017-2028
Table 12.6 Africa Hereditary Angioedema Market Forecast by Route of Administration: ($bn, AGR%) 2017-2028
Table 12.7 Africa Hereditary Angioedema Market by Route of Administration Forecast: CAGR (%), 2018-2023, 2023-2028, 2018-2028
Table 12.8 Africa Hereditary Angioedema Market Forecast by Distribution Channel: ($bn, AGR%) 2017-2028
Table 12.9 Africa Hereditary Angioedema Market by Distribution Channel Forecast: CAGR (%) 2018-2023, 2023-2028, 2018-2028
Table 13.1 BioCryst Pharmaceuticals, Inc. Profile 2016 (CEO, Total Company Sales $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.2 BioCryst Pharmaceuticals, Inc.: Key Developments
Table 13.3 CSL Limited Profile 2016 (CEO, Total Company Sales AUD m, Sales in the Market AUD m, Net Income / Loss AUD m, Net Capital Expenditure AUD m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.4 iBio Inc. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.5 Ionis Pharmaceuticals, Inc. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.6 Pharming Group NV Profile 2016 (CEO, Total Company Sales EUR m, Sales in the Market EUR m, Net Income / Loss EUR m, Net Capital Expenditure EUR m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.7 Pharming Group NV Profile: Key Developments
Table 13.8 Santarus, Inc. Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.9 Santarus, Inc.: Key Developments
Table 13.10 Shire PLC Profile 2016 (CEO, Total Company Sales $m, Sales in the Market $m, Net Income / Loss $m, Net Capital Expenditure $m, Strongest Business Region, Business Segment in the Market, HQ, Founded, No. of Employees, Ticker, Website)
Table 13.11 Shire PLC Profile: Key Developments
List of Figures
Figure 2.1 Global Hereditary Angioedema Market Segmentation Overview
Figure 2.2 Global Hereditary Angioedema Market Forecast: Value ($bn) and AGR%, 2017-2028
Figure 3.1 Global Hereditary Angioedema Market by Drug Class Forecast: (AGR %), 2018-2028
Figure 3.2 Global Hereditary Angioedema Market by Drug Class Segment Forecast: ($bn, AGR %), 2017-2028
Figure 3.3 Global Hereditary Angioedema Market 2018 & 2028: Market Share Split (%) & BPS Analysis by Drug Class
Figure 3.4 Global C1 Esterase Inhibitor Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 3.5 Global Selective Bradykinin B2 Receptor Antagonist Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 3.6 Global Kallikrein Inhibitor (Kalbitor) Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 3.7 Global Others Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 3.8 Global Hereditary Angioedema Market Attractiveness Index by Drug Class, 2018–2028
Figure 4.1 Global Hereditary Angioedema Market by Route of Administration Forecast: (AGR %), 2018-2028
Figure 4.2 Global Hereditary Angioedema Market by Route of Administration Forecast: ($bn, AGR %), 2018-2028
Figure 4.3 Global Hereditary Angioedema Market, Market Share Split & BPS Analysis by Route of Administration, 2018 & 2028
Figure 4.4 Global Intravenous Segment Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 4.5 Global Subcutaneous Injection Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 4.6 Global Oral Segment Submarket Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 4.7 Global Hereditary Angioedema Market Attractiveness Index by Route of Administration, 2018–2028
Figure 5.1 Global Hereditary Angioedema Market by Distribution Channel Forecast: (AGR %), 2018-2028
Figure 5.2 Global Hereditary Angioedema Market by Distribution Channel Segment Forecast 2018-2028 ($bn, AGR %)
Figure 5.3 Global Hereditary Angioedema Market, Market Share Split & BPS Analysis by Distribution Channel Segment, 2018–2028
Figure 5.4 Global Hereditary Angioedema Market Value ($bn) Forecast and AGR (%) by Hospital Pharmacies, 2017–2028
Figure 5.5 Global Hereditary Angioedema Market Value ($bn) Forecast and AGR (%) by Retail Pharmacies Segment, 2017–2028
Figure 5.6 Global Hereditary Angioedema Market Attractiveness Index by Distribution Channel, 2018–2028
Figure 6.1 Global Hereditary Angioedema Market by Region Forecast: AGR (%), 2018-2028
Figure 6.2 Global Hereditary Angioedema Market by Region Segment Forecast 2018-2028 ($bn, Global AGR %)
Figure 6.3 Global Hereditary Angioedema Market, Market Share Split & BPS Analysis by Region, 2018–2028
Figure 6.4 North America Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 6.5 Latin America Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 6.6 Europe Hereditary Angioedema Market Forecast: Value ($bn) Forecast and AGR (%), 2017–2028
Figure 6.7 Asia-Pacific Hereditary Angioedema Market Value ($bn) Forecast and AGR (%), 2017–2028
Figure 6.8 Global Hereditary Angioedema Market Value ($bn) Forecast and AGR (%) by Middle East, 2017–2028
Figure 6.9 Africa Hereditary Angioedema Market Value ($bn) Forecast and AGR (%), 2017–2028
Figure 6.10 Global Hereditary Angioedema Market Attractiveness Index by Region, 2018–2028
Figure 6.11 Global Hereditary Angioedema Market by Region Submarket Share Forecast 2018 (% Share)
Figure 6.12 Global Hereditary Angioedema Market by Region Submarket Share Forecast 2023 (% Share)
Figure 6.13 Global Hereditary Angioedema Market By Region Segment Submarket Share Forecast 2028 (% Share)
Figure 6.14 Global Hereditary Angioedema Market Share by Countries Market Forecast 2018 (% Share)
Figure 6.15 Global Hereditary Angioedema Market Share by Countries Market Forecast 2023 (% Share)
Figure 6.16 Global Hereditary Angioedema Market Share by Countries Market Forecast 2028 (% Share)
Figure 7.1 North America Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 7.2 North America Hereditary Angioedema Market by Country: AGR (%), 2018-2028
Figure 7.3 North America Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Figure 7.4 North America Hereditary Angioedema Market Share Split & BPS Analysis by Country, 2018–2028
Figure 7.5 US Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 7.6 Canada Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 7.7 North America Hereditary Angioedema Market by Country Submarket Share Forecast 2018 (% Share)
Figure 7.8 North America Hereditary Angioedema Market by Country Submarket Share Forecast 2023 (% Share)
Figure 7.9 North America Hereditary Angioedema Market by Country Submarket Share Forecast 2028 (% Share)
Figure 7.10 North America Hereditary Angioedema Market Attractiveness Index by Drug Class, 2018–2028
Figure 7.11 North America Hereditary Angioedema Market Attractiveness Index by Route of Administration, 2018–2028
Figure 7.12 North America Hereditary Angioedema Market Attractiveness Index by Distribution Channel, 2018–2028
Figure 7.13 North America Hereditary Angioedema Market Attractiveness Index by Country, 2018–2028
Figure 8.1 Latin America Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 8.2 Latin America Hereditary Angioedema Market by Country Forecast: AGR (%), 2017-2028
Figure 8.3 Latin America Hereditary Angioedema Market by Country Forecast: ($bn, Latin America AGR %). 2017-2028
Figure 8.4 Latin America Hereditary Angioedema Market, Market Share Split & BPS Analysis by Country, 2018–2028
Figure 8.5 Brazil Hereditary Angioedema Market Value ($bn) Forecast and AGR (%), 2017–2028
Figure 8.6 Mexico Hereditary Angioedema Market Value ($bn) Forecast and AGR (%), 2017–2028
Figure 8.7 Rest of Latin America Hereditary Angioedema Market Value (US$ Bn) Forecast and AGR (%), 2017–2028
Figure 8.8 Latin America Hereditary Angioedema Market by Country Submarket Share Forecast 2018 (% Share)
Figure 8.9 Latin America Hereditary Angioedema Market by Country Submarket Share Forecast 2023 (% Share)
Figure 8.10 Latin America Hereditary Angioedema Market by Country Submarket Share Forecast 2028 (% Share)
Figure 8.11 Latin America Hereditary Angioedema Market Attractiveness Index by Drug Class, 2018–2028
Figure 8.12 Latin America Hereditary Angioedema Market Attractiveness Index by Route of Administration, 2018–2028
Figure 8.13 Latin America Hereditary Angioedema Market Attractiveness Index by Distribution Channel, 2018–2028
Figure 8.14 Latin America Hereditary Angioedema Market Attractiveness Index by Country, 2018–2028
Figure 9.1 Europe Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.2 Europe Hereditary Angioedema Market by Country Forecast: (AGR %), 2018-2028
Figure 9.3 Europe Hereditary Angioedema Market by Country Forecast: ($bn, Europe AGR %), 2018-2028
Figure 9.4 Europe Hereditary Angioedema Market, Market Share Split & BPS Analysis by Country, 2018–2028
Figure 9.5 UK Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.6 France Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.7 Germany Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.8 Italy Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.9 Spain Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.10 Russia Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.11 Rest of Europe Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 9.12 Europe Hereditary Angioedema Market by Country Submarket Share Forecast 2018 (% Share)
Figure 9.13 Europe Hereditary Angioedema Market by Country Submarket Share Forecast 2023 (% Share)
Figure 9.14 Europe Hereditary Angioedema Market by Country Submarket Share Forecast 2028 (% Share)
Figure 9.15 Europe Hereditary Angioedema Market Attractiveness Index by Drug Class, 2018–2028
Figure 9.16 Europe Hereditary Angioedema Market Attractiveness Index by Route of Administration, 2018–2028
Figure 9.17 Europe Hereditary Angioedema Market Attractiveness Index by Distribution Channel, 2018–2028
Figure 9.18 Europe Hereditary Angioedema Market Attractiveness Index by Country, 2018–2028
Figure 10.1 Asia-Pacific Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.2 Asia-Pacific Hereditary Angioedema Market by Country Forecast: (AGR %), 2018-2028
Figure 10.3 Asia-Pacific Hereditary Angioedema Market by Country Forecast: ($bn, Asia-Pacific AGR %), 2017-2028
Figure 10.4 Asia-Pacific Hereditary Angioedema Market: Market Share Split & BPS Analysis by Country, 2018–2028
Figure 10.5 China Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.6 India Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.7 Australia & New Zealand Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.8 Japan Hereditary Angioedema Market Value Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.9 ASEAN Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.10 South Korea Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.11 Rest of Asia-Pacific Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 10.12 Asia-Pacific Hereditary Angioedema Market by Country Submarket Share Forecast 2018 (% Share)
Figure 10.13 Asia-Pacific Hereditary Angioedema Market by Country Submarket Share Forecast 2023 (% Share)
Figure 10.14 Asia-Pacific Hereditary Angioedema Market by Country Submarket Share Forecast 2028 (% Share)
Figure 10.15 Asia-Pacific Hereditary Angioedema Market Attractiveness Index by Drug Class, 2018–2028
Figure 10.16 Asia-Pacific Hereditary Angioedema Market Attractiveness Index by Route of Administration, 2018–2028
Figure 10.17 Asia-Pacific Hereditary Angioedema Market Attractiveness Index by Distribution Channel, 2018–2028
Figure 10.18 Asia-Pacific Hereditary Angioedema Market Attractiveness Index by Country, 2018–2028
Figure 11.1 Middle East Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 11.2 Middle East Hereditary Angioedema Market by Country Forecast: AGR (%), 2018-2028
Figure 11.3 Middle East Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Figure 11.4 Middle East Hereditary Angioedema Market: Market Share Split & BPS Analysis by Country, 2018–2028
Figure 11.5 GCC Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 11.6 Israel Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 11.7 Rest of Middle East Hereditary Angioedema Market Forecast; Value ($bn) and AGR (%), 2017–2028
Figure 11.8 Middle East Hereditary Angioedema Market by Country Submarket Share Forecast 2018 (% Share)
Figure 11.9 Middle East Hereditary Angioedema Market by Country Submarket Share Forecast 2022 (% Share)
Figure 11.10 Middle East Hereditary Angioedema Market by Country Submarket Share Forecast 2028 (% Share)
Figure 11.11 Middle East Hereditary Angioedema Market Attractiveness Index by Drug Class, 2018–2028
Figure 11.12 Middle East Hereditary Angioedema Market Attractiveness Index by Route of Administration, 2018–2028
Figure 11.13 Middle East Hereditary Angioedema Market Attractiveness Index by Distribution Channel, 2018–2028
Figure 11.14 Middle East Hereditary Angioedema Market Attractiveness Index by Country, 2018–2028
Figure 12.1 Africa Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 12.2 Africa Hereditary Angioedema Market by Country Forecast: (AGR %), 2018-2028
Figure 12.3 Africa Hereditary Angioedema Market by Country Forecast: ($bn, AGR %), 2017-2028
Figure 12.4 Africa Hereditary Angioedema Market, Market Share Split & BPS Analysis by Country, 2018–2028
Figure 12.5 South Africa Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 12.6 Central Africa Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 12.7 North Africa Hereditary Angioedema Market Forecast: Value ($bn) and AGR (%), 2017–2028
Figure 12.8 Africa Hereditary Angioedema Market by Country Submarket Share Forecast 2018 (% Share)
Figure 12.9 Africa Hereditary Angioedema Market by Country Submarket Share Forecast 2023 (% Share)
Figure 12.10 Africa Hereditary Angioedema Market by Country Submarket Share Forecast 2028 (% Share)
Figure 12.11 Africa Hereditary Angioedema Market Attractiveness Index, by Drug Class, 2018–2028
Figure 12.12 Africa Hereditary Angioedema Market Attractiveness Index, by Route of Administration, 2018–2028
Figure 12.13 Africa Hereditary Angioedema Market Attractiveness Index, by Distribution Channel, 2018–2028
Figure 12.14 Africa Hereditary Angioedema Market Attractiveness Index by Country, 2018–2028
AmeriCare
BioCryst Pharmaceuticals, Inc
Clinigen Group plc
CSL Behring
CSL Intellectual Property
CSL Limited
Dyax Corp.
Fiocruz
HAEi International Patient Organization
iBio, Inc.
iBio, Inc.
Idera Pharmaceuticals
Inceptua Medicines Access
Ionis Pharmaceuticals, Inc.
Pharming Group NV
Prime Therapeutics LLC
Salix Pharmaceuticals, Inc.
Salix Pharmaceuticals, Ltd.
Sanquin Blood Supply
Santarus, Inc.
Seqirus
Shire plc
United States of America US Hereditary Angioedema Association
Valeant Pharmaceuticals International, Inc.
ViroPharma Inc.
World Allergy Organization
Download sample pages
Complete the form below to download your free sample pages for Global Hereditary Angioedema Market Forecast 2018-2028Download sample pages
Complete the form below to download your free sample pages for Global Hereditary Angioedema Market Forecast 2018-2028Any specific country, geo region, market segment or specific company information?
Email us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
If so, please drop an email to Sara Peerun stating your chosen report title to sara.peerun@visiongain.com
“Thank you for this Gene Therapy R&D Market report and for how easy the process was. Your colleague was very helpful and the report is just right for my purpose. This is the 2nd good report from Visiongain and a good price.”
Dr Luz Chapa Azuella, Mexico
American Association of Colleges of Pharmacy
American College of Clinical Pharmacy
American Pharmacists Association
American Society for Pharmacy Law
American Society of Consultant Pharmacists
American Society of Health-System Pharmacists
Association of Special Pharmaceutical Manufacturers
Australian College of Pharmacy
Biotechnology Industry Organization
Canadian Pharmacists Association
Canadian Society of Hospital Pharmacists
Chinese Pharmaceutical Association
College of Psychiatric and Neurologic Pharmacists
Danish Association of Pharmaconomists
European Association of Employed Community Pharmacists in Europe
European Medicines Agency
Federal Drugs Agency
General Medical Council
Head of Medicines Agency
International Federation of Pharmaceutical Manufacturers & Associations
International Pharmaceutical Federation
International Pharmaceutical Students’ Federation
Medicines and Healthcare Products Regulatory Agency
National Pharmacy Association
Norwegian Pharmacy Association
Ontario Pharmacists Association
Pakistan Pharmacists Association
Pharmaceutical Association of Mauritius
Pharmaceutical Group of the European Union
Pharmaceutical Society of Australia
Pharmaceutical Society of Ireland
Pharmaceutical Society Of New Zealand
Pharmaceutical Society of Northern Ireland
Professional Compounding Centers of America
Royal Pharmaceutical Society
The American Association of Pharmaceutical Scientists
The BioIndustry Association
The Controlled Release Society
The European Federation of Pharmaceutical Industries and Associations
The European Personalised Medicine Association
The Institute of Clinical Research
The International Society for Pharmaceutical Engineering
The Pharmaceutical Association of Israel
The Pharmaceutical Research and Manufacturers of America
The Pharmacy Guild of Australia
The Society of Hospital Pharmacists of Australia
Visiongain Pharma
Visiongain Pharma
Visiongain PharmaLatest Pharma news
Visiongain Publishes 3D Printing for Healthcare Market Report 2023-2033
The global 3D Printing for Healthcare market was valued at US$2,970.7 million in 2022 and is projected to grow at a CAGR of 23.6% during the forecast period 2023-2033.
27 September 2023
Visiongain Publishes Clinical Trial Supply and Logistics Market for Pharma 2023-2033
The global Clinical Trial Supply and Logistics for Pharma market is valued at US$13.8 billion in 2023 and is projected to grow at a CAGR of 8.4% during the forecast period 2023-2033.
25 September 2023
Visiongain Publishes Anti-infective Vaccines Market Report 2023-2033
The global Anti-infective Vaccines market is valued at US$48,360.4 million in 2023 and is projected to grow at a CAGR of 6.6% during the forecast period 2023-2033.
21 September 2023
Visiongain Publishes Contract Research Organisations (CROs) Market Report 2023-2033
The global Contract Research Organisations (CROs) market was valued at US$68.9 billion in 2023 and is projected to grow at a CAGR of 10.6% during the forecast period 2023-2033.
14 September 2023
